About the Role
The MSL, Oncology (Lung and/or Head & Neck Cancers) will join a fast-growing Field Medical Affairs team focused on commercializing the novel Signatera™ molecular residual disease test to oncologists and cancer researchers across solid tumors, with particular emphasis on lung and/or head and neck cancers, along with complementary products and services in Natera’s oncology portfolio. In 2019, the FDA designated Signatera as a Breakthrough Device, and Medicare proposed to cover its